Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

July 31, 2027

Conditions
DMDDuchenne Muscular DystrophyDuchenneExon 44
Interventions
DRUG

AOC 1044

AOC 1044 will be administered via intravenous (IV) infusion

Trial Locations (10)

27278

Rare Disease Research, Hillsborough

30329

Rare Disease Research - Atlanta, Atlanta

43215

Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus

55101

Gillette Children's Specialty Healthcare, Saint Paul

72202

Arkansas Children's Hospital, Little Rock

76208

Neurology Rare Disease Center, Denton

92037

University of California, San Diego, Rady's Children's Hospital, La Jolla

94070

Lucille Packard Children's Hospital at Stanford, San Carlos

95817

UC Davis Medical Center, Sacramento

01655

University of Massachusetts Medical School, Worcester

Sponsors
All Listed Sponsors
lead

Avidity Biosciences, Inc.

INDUSTRY